• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

johnsonandjohnson

Report: Chinese bidders eye Johnson & Johnson’s diabetes biz

January 17, 2018 By Brad Perriello

Johnson & Johnson

Chinese glucose monitor maker Sinocare (SZ:300298) and a sovereign wealth fund there are said to be in the hunt for the diabetes business Johnson & Johnson (NYSE:JNJ) is looking to unload. The New Brunswick, N.J.-based healthcare conglomerate early last year announced a strategic review of its LifeScan, Animas and Calibra Medical diabetes businesses and later elected to […]

Filed Under: Diabetes, Featured, Mergers & Acquisitions, Wall Street Beat Tagged With: chinainvestmentcorp, johnsonandjohnson, sinocare

Metavention raises $65m to tackle diabetes with metabolic neuromodulation therapy

January 9, 2018 By Sarah Faulkner

diabetes

Metavention said today that it closed a $65 million Series C round with funding from New Enterprise Associates, Sanderling Ventures and others. The medical device maker plans to use the funds to optimize its transcatheter-based metabolic neuromodulation therapy for people with Type II diabetes and prepare it for a Phase II trial in the U.S. […]

Filed Under: Diabetes, Featured, Funding Roundup, Personnel Tagged With: johnsonandjohnson, metavention

United Therapeutics dishes out $210m to settle charity-kickback claims

December 21, 2017 By Sarah Faulkner

Prescription drugs

United Therapeutics (NSDQ:UTHR) has agreed to pay $210 million to squash claims that it used a charity to illegally cover Medicare patients’ out-of-pocket costs in an attempt to boost sales. Drug companies are not allowed to subsidize co-pays for people enrolled in Medicare, but they can donate to independent non-profits that provide co-pay assistance. The settlement […]

Filed Under: Featured, Legal News, Pharmaceuticals, Wall Street Beat Tagged With: johnsonandjohnson, Pfizer Inc., United Therapeutics

Tandem looks to get in on ex-Animas customer base

October 25, 2017 By Sarah Faulkner

Tandem Diabetes

Tandem Diabetes Care (NSDQ:TNDM) and Dexcom (NSDQ:DXCM) announced yesterday that the companies would extend their existing joint welcome program aimed at luring Animas customers as Johnson & Johnson (NYSE:JNJ) bails out of the insulin pump biz. Tandem and Dexcom’s t:slim X2 welcome program was slated to end on Dec. 31, but the companies said yesterday that it would continue until […]

Filed Under: Diabetes, Drug-Device Combinations, Featured, Pharmaceuticals, Wall Street Beat Tagged With: animas, DexCom Inc., johnsonandjohnson, Tandem Diabetes Care

J&J’s LifeScan touts studies of OneTouch blood glucose monitoring system

October 24, 2017 By Sarah Faulkner

Johnson & Johnson

Two recently-published studies of LifeScan‘s OneTouch Verio Flex blood glucose monitoring system showed that the technology is accurate, reliable and linked with improvements in glycemic control, the Johnson & Johnson (NYSE:JNJ) business touted today. The release comes just days after the healthcare giant revealed that it plans to shut down its Animas insulin pump business and review […]

Filed Under: Diabetes, Featured, Patient Monitoring, Pharmaceuticals, Wall Street Beat Tagged With: johnsonandjohnson, lifescan

The 11 most innovative medical devices of 2017

October 19, 2017 By Danielle Kirsh

The nominees for the best medical technology of 2017 were recently announced for the 11th Annual Prix Galien USA Awards. The Galien Foundation, the host of the awards, hands out the Prix Galien Award annually to examples of outstanding biomedical and technology product achievement designed to improve human condition. Before candidates can qualify for the […]

Filed Under: Cardiovascular, Diabetes, Diagnostics, Featured, Hematology, Hospital Care, Imaging, Neurological, Oncology, Patient Monitoring, Research & Development, Surgical, Wound Care Tagged With: abbott, Allergan, Biosense Webster, Boston Scientific, BrainScope, DePuy Synthes, Ethicon, INSIGHTEC, Integra LifeSciences, johnsonandjohnson, Koning Corporation, medtech

Johnson & Johnson pharma revenue continues to climb in Q3

October 17, 2017 By Sarah Faulkner

Johnson & Johnson

Johnson & Johnson‘s (NYSE:JNJ) third quarter profits were down by -12%, the company reported today, but revenue topped expectations and the healthcare giant singled out its pharmaceutical business as a driving factor. “Johnson & Johnson accelerated growth in the third quarter. This is driven by the strong performance of our pharmaceutical business, and augmented by […]

Filed Under: Featured, MassDevice Earnings Roundup, Pharmaceuticals, Wall Street Beat Tagged With: johnsonandjohnson

Insulet looks to lure Animas users

October 10, 2017 By Sarah Faulkner

Insulet Omnipod

Just days after Johnson & Johnson (NYSE:JNJ) revealed that it plans to shut down its 410-worker Animas insulin pump subsidiary, Insulet (NSDQ:PODD) said it would offer existing Animas insulin pump users a free trial of the company’s Omnipod system. Insulet’s Welcome Program includes a free Omnipod tubeless insulin delivery system, built-in blood glucose meter and 30 days […]

Filed Under: Diabetes, Drug-Device Combinations, Featured, Pharmaceuticals, Wall Street Beat Tagged With: animas, Insulet, johnsonandjohnson, Medtronic

Johnson & Johnson to shutter Animas insulin pump biz

October 5, 2017 By Brad Perriello

Johnson & Johnson

Johnson & Johnson (NYSE:JNJ) said today that it plans to shut down its 410-worker Animas insulin pump subsidiary, offering to help some 90,000 Animas patients transfer to products made by rival Medtronic (NYSE:MDT). The Chesterbrook, Pa.-based company said it will stop making its Animas Vibe and OneTouch Ping pumps, but will continue to provide customer […]

Filed Under: Diabetes, Featured, Wall Street Beat Tagged With: animas, johnsonandjohnson

J&J’s Janssen wins $45m BARDA contract for Ebola vaccine dev

October 2, 2017 By Fink Densford

Janssen

Johnson & Johnson (NYSE:JNJ) said today that its Janssen Pharmaceutical subsidiary Janssen Vaccines & Prevention B.V received a $44.7 million award and collaborative partnership from the US Biomedical Advanced Research and Development Authority to support its development of an investigational Ebola vaccine regimen. The deal comes with an option for BARDA to provide additional funding over 5 […]

Filed Under: Business/Financial News, Featured, Funding Roundup, Research & Development Tagged With: Janssen Pharmaceuticals, johnsonandjohnson

  • « Go to Previous Page
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Interim pages omitted …
  • Page 8
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS